Tracked Trials
Every registered trial still open on a graded claim — who is running it, how big it is, and when it is due to report.
Public database · Harvested 24 August 2026
The Grade Ledger tells you what the evidence says today and what would move it. This page tells you when that might happen — the registered trials still open on each graded claim, who is running them, how many people are in them, and when they are due to report.
What this page is for
A grade only changes when new evidence arrives. Everything that could arrive is, by definition, already registered somewhere. Tracking the register is how re-grade alerts get sent before the news cycle catches up — and how you can see, today, which of our marks are genuinely in play and which are settled for years.
| Compound / claim | Shelf | Registered trial | n | Phase | Status | Due |
|---|---|---|---|---|---|---|
| MagnesiumImproves sleep quality | supplements | NCT07708857Magnesium Supplement for Sleep Quality in Women With Poor Sleep | 50 | NA | Not yet recruiting | Oct 2026 |
| MagnesiumImproves sleep quality | supplements | NCT06902285Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty | 64 | PHASE4 | Recruiting | Jul 2027 |
| Creatine monohydrateLean mass and strength | supplements | NCT06112990Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Can | 200 | PHASE3 | Recruiting | Nov 2028 |
| Creatine monohydrateLean mass and strength | supplements | NCT07625202Creatine Supplementation During GLP-1a Therapy | 40 | NA | Recruiting | May 2027 |
| AshwagandhaReduces perceived stress | supplements | NCT07647081The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women | 30 | NA | Not yet recruiting | Dec 2026 |
| Omega-3Lowers triglycerides | supplements | NCT07004777Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentrati | 375 | NA | Recruiting | Dec 2026 |
| Omega-3Lowers triglycerides | supplements | NCT07394517ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3 | 105 | NA | Not yet recruiting | Jan 2027 |
| Vitamin CPrevents the common cold | supplements | No open registered trial matched. The claim is already graded Strong / Not supported; the Cochrane review is unlikely to be overturned by a small trial. | — | |||
| CaffeineAlertness and performance | supplements | No open trial matched that targets alertness or performance specifically. Already graded Strong / Supported. | — | |||
| L-theanineAttention and focus | nootropics | No open trial matched that isolates the focus claim. | — | |||
| Lion's ManeMemory and focus | nootropics | No open registered trial matched. The grade stays Emerging until someone runs one. | — | |||
| ResveratrolMetabolic health | longevity | NCT07245979Supplementation With Sirtuin Activators in Women With Increased Body Weight | 120 | NA | Recruiting | Nov 2026 |
| NMNSlows biological ageing | longevity | NCT06907329The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence an | 126 | NA | Recruiting | Mar 2027 |
| NMNSlows biological ageing | longevity | NCT07144527Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy | 40 | NA | Recruiting | Dec 2026 |
| Testosterone (TRT)Cardiovascular safety | hormones | No open trial matched that targets cardiovascular safety. The mark rests on TRAVERSE. | — | |||
| BPC-157Tendon / soft-tissue healing | peptides | NCT07437547BPC 157 for Acute Hamstring Muscle Strain Repair | 120 | PHASE2 | Recruiting | Feb 2027 |
| TB-500Injury recovery | peptides | NCT07487363TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | 80 | PHASE1/PHASE2 | Recruiting | Feb 2027 |
| TB-500Injury recovery | peptides | NCT07586865Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction | 189 | PHASE2 | Not yet recruiting | Aug 2027 |
| MK-677Muscle and strength | peptides | NCT06948214Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency | 150 | PHASE3 | Recruiting | Dec 2027 |
| LGD-4033Muscle growth | sarms | Nothing registered. No human efficacy trial is currently open anywhere in the registry for this compound. | — | |||
| RAD-140Muscle growth | sarms | Nothing registered. No human efficacy trial is currently open anywhere in the registry for this compound. | — | |||
| CardarineEndurance | sarms | Nothing registered. Development was abandoned; no human trial is open. | — | |||
How this list was built
Every row comes from the ClinicalTrials.gov public API, queried on 24 August 2026. We asked for interventional studies naming each compound as an intervention, restricted to studies still open — recruiting, not yet recruiting, enrolling by invitation, or active but closed to enrolment — and discarded any without a stated primary completion date. From what came back we kept the trials whose design could actually move the published mark, and said so plainly where none could.
What "nothing pending" does and does not mean. It means no open, dated, interventional study matched our query for that compound and claim. It does not mean no such study exists anywhere — registries are incomplete, trials are registered late, and non-registry research happens. Treat an empty row as "nothing visible is coming", not as proof of absence. Where we say a compound has nothing registered at all, that is a stronger statement, and for the three SARMs on this page it is the single most important fact about them.
Primary completion dates are the sponsor's own estimate and slip routinely. A date here is the earliest a read-out is plausible, not a promise. We re-harvest this page quarterly and on any re-grade.
Bottom line
Three of the compounds we grade — LGD-4033, RAD-140 and Cardarine — have no open registered human trial of any kind. Their marks are not provisional pending new data. There is no new data coming.
At the other end, BPC-157 has a registered Phase 2 trial in 120 people due February 2027. It is currently graded Preliminary / Untested in humans. If that trial reports, it will be the first thing that has ever qualified under our rubric for this compound — and the grade will move for the first time.